vs

Side-by-side financial comparison of Kennedy-Wilson Holdings, Inc. (KW) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Kennedy-Wilson Holdings, Inc. is the larger business by last-quarter revenue ($120.6M vs $37.2M, roughly 3.2× Organogenesis Holdings Inc.). On growth, Kennedy-Wilson Holdings, Inc. posted the faster year-over-year revenue change (-11.0% vs -57.1%). Over the past eight quarters, Kennedy-Wilson Holdings, Inc.'s revenue compounded faster (-6.0% CAGR vs -46.5%).

Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

KW vs ORGO — Head-to-Head

Bigger by revenue
KW
KW
3.2× larger
KW
$120.6M
$37.2M
ORGO
Growing faster (revenue YoY)
KW
KW
+46.1% gap
KW
-11.0%
-57.1%
ORGO
Faster 2-yr revenue CAGR
KW
KW
Annualised
KW
-6.0%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
KW
KW
ORGO
ORGO
Revenue
$120.6M
$37.2M
Net Profit
$58.0M
Gross Margin
30.8%
Operating Margin
57.3%
-185.1%
Net Margin
48.1%
Revenue YoY
-11.0%
-57.1%
Net Profit YoY
32.7%
EPS (diluted)
$0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KW
KW
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$120.6M
$225.6M
Q3 25
$116.4M
$150.9M
Q2 25
$135.7M
$101.0M
Q1 25
$128.3M
$86.7M
Q4 24
$135.5M
$126.7M
Q3 24
$127.5M
$115.2M
Q2 24
$132.0M
$130.2M
Net Profit
KW
KW
ORGO
ORGO
Q1 26
Q4 25
$58.0M
$43.7M
Q3 25
$-10.2M
$21.6M
Q2 25
$5.6M
$-9.4M
Q1 25
$-29.6M
$-18.8M
Q4 24
$43.7M
$7.7M
Q3 24
$-66.8M
$12.3M
Q2 24
$-48.3M
$-17.0M
Gross Margin
KW
KW
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
KW
KW
ORGO
ORGO
Q1 26
-185.1%
Q4 25
57.3%
28.1%
Q3 25
-6.2%
13.7%
Q2 25
7.4%
-12.5%
Q1 25
-26.9%
-30.9%
Q4 24
36.7%
8.1%
Q3 24
-60.8%
5.4%
Q2 24
-45.5%
-10.7%
Net Margin
KW
KW
ORGO
ORGO
Q1 26
Q4 25
48.1%
19.4%
Q3 25
-8.8%
14.3%
Q2 25
4.1%
-9.3%
Q1 25
-23.1%
-21.7%
Q4 24
32.3%
6.1%
Q3 24
-52.4%
10.7%
Q2 24
-36.6%
-13.1%
EPS (diluted)
KW
KW
ORGO
ORGO
Q1 26
Q4 25
$0.22
$0.31
Q3 25
$-0.15
$0.11
Q2 25
$-0.05
$-0.10
Q1 25
$-0.30
$-0.17
Q4 24
$0.24
$0.05
Q3 24
$-0.56
$0.09
Q2 24
$-0.43
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KW
KW
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$184.5M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
Total Assets
$6.6B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KW
KW
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$184.5M
$93.7M
Q3 25
$382.6M
$63.7M
Q2 25
$309.1M
$73.1M
Q1 25
$356.6M
$110.0M
Q4 24
$217.5M
$135.6M
Q3 24
$367.1M
$94.3M
Q2 24
$366.5M
$89.9M
Total Debt
KW
KW
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
KW
KW
ORGO
ORGO
Q1 26
Q4 25
$1.5B
$300.1M
Q3 25
$1.5B
$255.1M
Q2 25
$1.6B
$233.2M
Q1 25
$1.6B
$242.9M
Q4 24
$1.6B
$262.9M
Q3 24
$1.6B
$278.5M
Q2 24
$1.7B
$263.5M
Total Assets
KW
KW
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$6.6B
$598.7M
Q3 25
$6.7B
$509.8M
Q2 25
$6.8B
$461.1M
Q1 25
$7.2B
$467.4M
Q4 24
$7.0B
$497.9M
Q3 24
$7.4B
$446.3M
Q2 24
$7.5B
$443.2M
Debt / Equity
KW
KW
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KW
KW
ORGO
ORGO
Operating Cash FlowLast quarter
$11.4M
Free Cash FlowOCF − Capex
$-55.2M
FCF MarginFCF / Revenue
-45.8%
Capex IntensityCapex / Revenue
55.2%
Cash ConversionOCF / Net Profit
0.20×
TTM Free Cash FlowTrailing 4 quarters
$-103.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KW
KW
ORGO
ORGO
Q1 26
Q4 25
$11.4M
$39.4M
Q3 25
$-7.6M
$3.1M
Q2 25
$42.0M
$-32.9M
Q1 25
$-51.9M
$-19.9M
Q4 24
$55.1M
$10.9M
Q3 24
$-5.6M
$8.7M
Q2 24
$36.7M
$4.7M
Free Cash Flow
KW
KW
ORGO
ORGO
Q1 26
Q4 25
$-55.2M
$34.8M
Q3 25
$-18.0M
$844.0K
Q2 25
$29.4M
$-36.5M
Q1 25
$-59.7M
$-23.6M
Q4 24
$-76.5M
$7.6M
Q3 24
$-27.7M
$6.1M
Q2 24
$-500.0K
$2.9M
FCF Margin
KW
KW
ORGO
ORGO
Q1 26
Q4 25
-45.8%
15.4%
Q3 25
-15.5%
0.6%
Q2 25
21.7%
-36.1%
Q1 25
-46.5%
-27.2%
Q4 24
-56.5%
6.0%
Q3 24
-21.7%
5.3%
Q2 24
-0.4%
2.2%
Capex Intensity
KW
KW
ORGO
ORGO
Q1 26
Q4 25
55.2%
2.1%
Q3 25
8.9%
1.5%
Q2 25
9.3%
3.6%
Q1 25
6.1%
4.2%
Q4 24
97.1%
2.7%
Q3 24
17.3%
2.2%
Q2 24
28.2%
1.4%
Cash Conversion
KW
KW
ORGO
ORGO
Q1 26
Q4 25
0.20×
0.90×
Q3 25
0.14×
Q2 25
7.50×
Q1 25
Q4 24
1.26×
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KW
KW

Consolidated Portfolio Segment$84.9M70%
Investment Management Fees$30.4M25%
Real Estate$5.1M4%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons